Amytrx Therapeutics, Inc.

NASHVILLE, Tenn., Nov. 7, 2023 /PRNewswire/ -- Amytrx Therapeutics, a leading biopharmaceutical company specializing in the development of novel therapies for dermatology and inflammation, is pleased to announce the addition of two distinguished scientists to its Board of Directors. This strategic move represents a significant step forward in the company's commitment to expanding its leadership team with experts who possess deep scientific knowledge in the field. Continue Reading The newly appointed board members, Dr. Michael Howell and Dr. Satish Joshi, bring a wealth of experience and expertise to Amytrx Therapeutics. Their scientific background and business acumen will play a pivotal role in advancing the company's mission to bring innovative treatments to market, with a primary focus on AMTX-100, a groundbreaking anti-inflammatory peptide. Amytrx Therapeutics adds top industry specialists to their Board Post this Dr. Michael Howell, a renowned immunologist with more than 20 years of experience in allergy, autoimmunity, dermatology, inflammatory and oncology diseases, has a distinguished record of contributions to the dermatology field. Dr. Howell has played a pivotal role in numerous clinical trials and has published extensively on topics related to dermatological and immunological conditions. He also participated in the development of many biological and small molecule drugs currently in the market or in development. His extensive knowledge of the field will be invaluable as Amytrx Therapeutics continues its journey to revolutionize care for inflammatory skin diseases. Dr. Satish Joshi, a respected technocrat in peptide solutions with over 25 years of experience in the peptide API business, has been at the forefront of peptide product development throughout his career. His work has led to several successful strategic business initiatives in the peptide and biochemical therapeutic industry. Dr. Joshi's expertise will be instrumental as Amytrx Therapeutics strives to develop strategic partnerships that further the development of therapeutics for patients suffering from inflammation-related conditions. "Amytrx Therapeutics is excited to welcome Dr. Howell and Dr. Joshi to our Board of Directors," said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics. "Their exceptional scientific and business backgrounds align perfectly with our mission to bring transformative treatments to patients in need. Their contributions will be invaluable as we continue to advance our lead candidate, AMTX-100, and work towards its successful commercialization." Amytrx Therapeutics is committed to enhancing its leadership team with scientific experts who can contribute to the development and commercialization of innovative therapies. With the addition of Dr. Michael Howell and Dr. Satish Joshi, the company is poised to strengthen its position in the dermatology and inflammation industry, bringing together skilled specialists who will drive the success of the organization. The company's flagship product, AMTX-100, is a promising anti-inflammatory peptide that has shown great potential in preclinical and clinical studies. Amytrx Therapeutics remains dedicated to advancing AMTX-100 through clinical trials and regulatory processes, ultimately providing a new hope for patients suffering from inflammation-related disorders. For more information about Amytrx Therapeutics and its groundbreaking work in the dermatology and inflammation industry, please visit . Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world's most debilitating diseases. SOURCE Amytrx Therapeutics

NASHVILLE, Tenn., July 25, 2023 /PRNewswire/ -- Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, has announced that their abstract from the Revolutionizing Atopic Dermatitis (RAD) Conference has been published in the British Journal of Dermatology. The abstract, featured at the RAD Conference earlier this year in Washington, DC highlights exciting data that demonstrates the promising safety, tolerability, and efficacy outcomes observed with AMTX-100 in a Phase 1 clinical trial in adults with mild to moderate atopic dermatitis. Atopic dermatitis (AD) is a chronic skin condition that affects nearly 16.5 million adults in the United States and is predominantly associated with Th2-mediated inflammation, allergen sensitization, microbial invasion, and intense pruritus. Despite recent advancements, there remains a clear need for a novel non-steroidal topical agent that is both highly effective and not burdened with adverse event concerns. AMTX-100 is a novel peptide currently being developed by Amytrx Therapeutics for the treatment of inflammatory conditions. In the Phase 1 study, patients receiving the investigational therapy experienced substantial improvements in key disease-related parameters, including reduced pruritus and diminished inflammation as assessed by a visible decrease in affected body surface area. Importantly, the therapy defined maximum-tolerated dosage, as well as safety, tolerability, and efficacy, with no significant adverse events reported during the study period. Dr. Michael Howell, a Scientific Advisor to Amytrx, expressed enthusiasm, stating, "The results from this clinical trial demonstrate the therapeutic benefit for AMTX-100 in patients with mild to moderate atopic dermatitis. This work additionally signifies an important step forward in our mission to develop a safe and effective therapy for atopic dermatitis." The publication of Amytrx Therapeutics' abstract in the British Journal of Dermatology reinforces the therapeutic potential of their leading peptide formula AMTX-100, a novel, chimeric, 100% human peptide that modulates inflammation and coincides with open enrollment for the next leg of clinical trials in a Phase 2 study of AMTX-100 in atopic dermatitis patients. About Amytrx Therapeutics Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world's most debilitating diseases. For further information, please visit . SOURCE Amytrx Therapeutics

NASHVILLE, June 28, 2023 /PRNewswire/ -- Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3, a groundbreaking anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis. This milestone marks a significant step forward in the development of advanced treatment options for individuals affected by this chronic and debilitating skin condition. Continue Reading The trial's primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of safety. Tweet this Amytrx Therapeutics is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3, a groundbreaking anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis. Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1). Despite the availability of various treatment options, there remains an unmet need for more effective and safer therapies. With this topical formulation of AMTX-100 CF3, Amytrx Therapeutics aims to revolutionize the treatment landscape and offer hope to those living with atopic dermatitis. The Phase 2b clinical trial will continue to build upon a recent trial that has evaluated the safety and efficacy of AMTX-100 CF3 in a larger cohort of adult patients that has shown favorable efficacy bypassing the need for rescue steroid treatment. This randomized, double-blind, placebo-controlled study will be conducted at 8-10 clinical sites across the country. This study is seeking 60 participants to generate a 1:1 ratio between placebo and active arms of the study. The trial's primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of treatment safety. This clinical trial will include a 28-day treatment period with twice daily treatment and a 2-week follow-up assessment post-treatment to determine therapeutic efficacy. In addition, participants will receive a topical emollient 2-weeks prior to trial to exclude participants who may be impacted by a placebo effect. Precision medicine techniques will also be used to assess changes in the expression of genes involved in inflammation. "We are thrilled to initiate the open enrollment for our Phase 2b clinical trial of AMTX-100 CF3," said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics. "At Amytrx, we are committed to developing innovative therapies that can make a meaningful difference in the lives of patients. This trial represents a crucial step towards bringing a safe and targeted treatment option to adults suffering from atopic dermatitis, in addition to other chronic inflammatory skin diseases such as psoriasis, vitiligo, lupus, graft vs. host, and more." Amytrx Therapeutics has invested years of research and development into the creation of AMTX-100 CF3. This unique topical formulation of their anti-inflammatory peptide has shown promising results in preclinical and clinical studies. AMTX-100 CF3 utilizes a novel untapped intracellular target to control inflammation. The company believes that AMTX-100 CF3 has the potential to provide durable relief, enhance quality of life, and minimize the burden of this chronic condition with a revolutionary approach that interacts with a key checkpoint in the initiation of inflammation. The open enrollment for the Phase 2b clinical trial of AMTX-100 CF3 is now underway. Eligible adults interested in participating or learning more about the trial are encouraged to visit the ClinicalTrials.Gov listing # NCT04313400 or visit Amytrx Therapeutics' website at . The company welcomes collaboration with research institutions that wish to contribute to advancing the knowledge and treatment of other inflammatory skin disorders. The current topical formulation of AMTX-100 CF3 being studied in the Phase 2b clinical trial provides an example of the various formulations available for novel anti-inflammatory peptide AMTX-100. Amytrx Therapeutics is actively exploring other delivery methods to cater to the diverse needs of patients across a variety of inflammatory diseases. These formulations include oral, injectable, nasal spray, and other options. This comprehensive approach underscores Amytrx Therapeutics' commitment to developing a range of therapeutic options that can effectively target inflammation and provide additional treatment strategies. About Amytrx Therapeutics Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world's most debilitating diseases. For further information, please visit . Kapur, S., Watson, W., & Carr, S. (2018). Atopic dermatitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 52. SOURCE Amytrx Therapeutics